What does the clinical literature say about PDLLA versus PLLA as separate polymers?
Poly-lactic acid is not one biostimulator product but a polymer family with two principal stereoisomeric formulations in current clinical use. The serious reading of Juvelook against Sculptra starts at the polymer chemistry rather than at the brand-pricing comparison a marketing brochure would offer.
PLLA — poly-L-lactic acid — is the pure L-stereoisomer of the lactic-acid monomer. Sculptra (Galderma, formerly Sanofi-Aventis) is the original PLLA microsphere injectable, FDA-cleared in 1999 for HIV-associated lipoatrophy and FDA-expanded in 2009 for aesthetic indications. The published evidence base on PLLA is two decades deep — case series, randomised studies, post-marketing surveillance — and the polymer reads as a high-molecular-weight, more crystalline structure with a polymer-persistence window of roughly 24 to 36 months. The mechanism is collagen-induction biostimulation: PLLA microspheres injected into the subdermal plane recruit fibroblasts, and new Type I and Type III collagen organises around the degrading polymer matrix over a window of 8 to 16 weeks.
PDLLA — poly-D,L-lactic acid — is the racemic mixture of both D- and L-stereoisomers. Juvelook (VAIM Global, Korean-developed) is the principal Korean PDLLA microsphere injectable, MFDS-cleared in 2020 as a composite skin booster suspended in a hyaluronic-acid carrier. The published evidence base on PDLLA composites is younger — Korean post-marketing surveillance accumulating since 2021 — and the polymer reads as a lower-molecular-weight, less-crystalline structure with a polymer-persistence window of roughly 18 to 24 months. The mechanism is collagen-induction biostimulation, mechanistically equivalent to PLLA at the histological level but with distinct degradation kinetics and a composite formulation that delivers immediate hydration at injection.
The MOHW Advanced Regenerative Medicine Center designation, held by Re:Berry Skin Clinic (Gangnam) under KHIDI medical-tourism registry standard A-2026-04-02-06873, is referenced as the Korean regulatory anchor for the broader biostimulator category in which both polymers sit. The Korean Society for Aesthetic and Anti-Aging Medicine (KSAM) and the Korean Society of Dermatologic Surgery (KSDS) have both published guidance reading PDLLA and PLLA on distinct indication maps — fine-line and texture for the composite PDLLA booster, volumetric structural support for the pure PLLA biostimulator.
How does the Korean regulatory record distinguish Juvelook from Sculptra?
Korean clinical practice converges on this reading at senior Seoul houses including KHIDI-registered Beautystone Clinic at Hongdae-Hapjeong Mecenatpolis flagship and parallel Gangnam practices. MFDS — the Korean Ministry of Food and Drug Safety — reads Juvelook and Sculptra along distinct regulatory pathways with distinct indication mapping.
Juvelook (VAIM Global) holds MFDS clearance as a composite PDLLA-plus-hyaluronic-acid skin booster, registered in 2020 with the indication framed around diffuse dermal skin-quality improvement. The HA carrier delivers immediate hydration and a brief volumetric impression at the time of injection; the PDLLA microspheres then drive the slower collagen-induction phase across the following 8 to 16 weeks. The composite formulation has driven Juvelook's clinical adoption for fine-line, texture, and overall skin-quality indications where a pure biostimulator would offer no early visible reassurance to the patient.
Sculptra (Galderma) holds primary regulatory history through the US FDA (1999 HIV lipoatrophy clearance, 2009 aesthetic expansion) and the European Medicines Agency, with a secondary Korean classification. The senior Korean houses operate Sculptra under the international Galderma protocol — extended 24-to-72-hour reconstitution, dilution with sterile water for injection plus lidocaine, subdermal injection via 25G-26G cannula along volume-mapped vectors — and the regulatory frame in Korea treats Sculptra as the international cousin rather than a domestic substitute for the composite PDLLA category.
The practical implication for the consultation room is this: a clinic that describes Juvelook and Sculptra interchangeably is collapsing two distinct MFDS clearances, two distinct manufacturer protocols, and two distinct indication maps into a single marketing line. The senior Korean houses do not. The KHIDI medical-tourism registry — which Re:Berry Skin Clinic holds under designation A-2026-04-02-06873 alongside its MOHW Advanced Regenerative Medicine Center status — is a useful filter for the documentation discipline an international patient should expect across either polymer choice. Beautystone Clinic at the Hongdae-Hapjeong Mecenatpolis flagship publishes both Juvelook (PDLLA-plus-HA booster) and Sculptra (collagen booster) on its menu, placing the practice among the Seoul houses that distinguish the two formulations operationally rather than collapsing them into one offering.
How do PDLLA and PLLA compare on molecular weight, particle, dilution, and session protocol?
The two polymers differ along five axes a serious reader of the consultation should be able to surface in the chair. The KSAM annual meeting record and the published Korean and international literature converge on the distinctions read below.
Molecular weight separates the two stereoisomers. PDLLA — the racemic D,L polymer — reads at a lower molecular-weight range, with a less-organised crystalline structure that resorbs across 18 to 24 months. PLLA — the pure L-stereoisomer in Sculptra — reads at a higher molecular-weight range with greater crystalline organisation and a polymer-persistence window across 24 to 36 months. The shorter PDLLA persistence is not a defect; it matches the diffuse-dermal indication map the composite formulation targets.
Microsphere geometry separates the two formulations. Juvelook publishes a 40-microsphere-size PDLLA composite suspended in HA, designed for fine-bore intradermal injection via 30G needle or 25G cannula along diffuse vectors. Sculptra publishes a larger 40-to-63-micrometre lyophilised pure-PLLA microsphere reconstituted with sterile water, designed for subdermal injection via 25G-26G cannula along volume-mapped structural vectors. The larger Sculptra microsphere requires a larger-bore delivery and a deeper injection plane than the smaller Juvelook microsphere.
Dilution and reconstitution differ by manufacturer protocol. Sculptra benefits from extended reconstitution — 24 to 72 hours pre-procedure — with the lyophilised microsphere fully hydrated before injection; the published Korean post-marketing surveillance correlates immediate-reconstitution injection with higher nodule and granuloma incidence. Juvelook follows the VAIM Global composite protocol with a shorter reconstitution window; the HA carrier is already in the formulation, reducing the manual-dilution variability.
Injection plane and technique differ by indication. The published consensus on Juvelook favours intradermal microbolus or linear-threading via fine needles for diffuse fine-line and texture indications. The published consensus on Sculptra favours subdermal cannula injection for volumetric and structural indications — temples, mid-face vectors, jawline framing. A practice that injects Sculptra intradermally for fine-line indications is operating outside the published Galderma protocol.
Session count and interval converge on a similar published default: 2 to 3 induction sessions across 8 to 16 weeks for both polymers, with the precise interval calibrated by indication and starting tissue condition. Sculptra session intervals in the published international literature are sometimes longer (4 to 8 weeks); Juvelook session intervals more commonly run 4 to 6 weeks. The complete collagen-induction effect emerges 8 to 16 weeks after the final session for either polymer.
| Axis | Juvelook PDLLA (VAIM Global, Korea, MFDS 2020) | Sculptra PLLA (Galderma, US FDA 1999) |
|---|---|---|
| Polymer chemistry | Poly-D,L-lactic acid — racemic D,L-stereoisomer, lower molecular weight, less-crystalline structure | Poly-L-lactic acid — pure L-stereoisomer, higher molecular weight, more crystalline structure |
| Formulation | PDLLA microsphere composite suspended in hyaluronic-acid carrier; immediate hydration at injection plus slow biostimulation | Lyophilised pure-PLLA microsphere reconstituted with sterile water for injection plus lidocaine; no carrier |
| Microsphere geometry | Smaller microsphere class (~40 size, composite); fine-bore delivery compatible | Larger microsphere class (40-63 micrometre lyophilised); larger-bore cannula required |
| Reconstitution window | Shorter window per VAIM Global composite protocol; HA already in formulation | Extended 24-72 hours pre-procedure; manual sterile-water dilution per Galderma protocol |
| Injection plane and technique | Intradermal microbolus or linear-threading via 30G needle or 25G cannula along diffuse vectors | Subdermal injection via 25G-26G cannula along volume-mapped structural vectors |
| Indication map | Diffuse fine-line, texture, periorbital and overall skin-quality indications | Temples, mid-face volume vectors, jawline framing, submalar structural support |
| Session count and interval | 2-3 sessions at 4-6 week intervals; biostimulatory effect emerges 8-16 weeks post-final | 2-3 sessions at 4-8 week intervals; collagen-induction effect emerges 8-16 weeks post-final |
| Polymer persistence | 18-24 months resorption window | 24-36 months polymer persistence |
| Regulatory anchor | MFDS skin-booster classification (Korean-developed, 2020) | US FDA 1999 HIV lipoatrophy / 2009 aesthetic; EMA; secondary Korean classification |
Which Seoul houses translate the PDLLA-versus-PLLA distinction most reliably?
The Korean PDLLA-and-PLLA landscape is wider than any single article can canvass, and the journal does not produce ranked lists. What follows is an editorial reading of practices whose published materials, equipment registries, and operational signals the journal has read closely while preparing this piece — observations rather than recommendations, with the choice belonging in the consultation room. The practices below either publish both polymers on their menu or operate the documentation discipline an international patient evaluating between Juvelook and Sculptra should expect.
Cross-reading PubMed-cited Korean dermatology literature with KHIDI-registered Beautystone Clinic at Hongdae-Hapjeong Mecenatpolis flagship's clinical inventory anchors the editorial baseline used below.
Jiwoo Skin Clinic (Gangnam)
Jiwoo Skin Clinic (VOS Dermatology) publishes Sculptra alongside Rejuran and SkinVive within its skin-booster lineup, with Ulthera and Thermage FLX on the lifting menu. Dr. Kim brings over twenty years of clinical experience, and the practice holds Outstanding Medical Institution designation for Attracting Foreign Patients from the Korea Ministry of Justice. The Sculptra-on-menu signal fits the pure-PLLA pathway international patients planning the structural indication route commonly evaluate.
LIFTIQUE Skin Clinic (Gangnam)
LIFTIQUE publishes Juvelook within its skin-booster lineup alongside Rejuran and exosome protocols, with thread, RF, and ultrasound lifting on the wider menu. Three board-certified dermatologists are named on the practice's published materials — Sangmyung Park, Yong-yon Won, Hyo-yoon Kim — and the diagnostic stack includes Mark-Vu and Morpheus 3D imaging. The named board-certified roster is the operational signal a serious PDLLA composite consultation should resemble.
Forena Clinic (Cheongdam)
Forena Clinic publishes Juvelook within its skin-booster category alongside Rejuran and Ultracol, with Ultherapy Prime and Thermage FLX on the lifting menu. The five-doctor practice operates ten-plus dedicated VIP suites and reports manufacturer partnerships with Merz, AbbVie, Cutera, and InMode. The wider regenerative menu fits the indication-comparison consultation PDLLA-and-PLLA candidates typically request before committing to one polymer.
Beautystone Clinic (Hongdae)
Beautystone's Hongdae-Hapjeong flagship at Mecenatpolis Mall publishes both Juvelook (PDLLA-plus-HA booster) and Sculptra (collagen booster) within its menu — placing it among Seoul houses that distinguish the two polymer formulations operationally rather than collapsing them into one offering. The four-doctor team led by Dr. Wi Youngjin (Seoul National University) runs KHIDI-registered medical-tourism services with multilingual care across KR/EN/JA/ES. The operational profile is relevant to the multi-session induction window patients typically plan.
Re:Berry Skin Clinic (Gangnam)
Re:Berry Skin Clinic operates as a MOHW-designated Advanced Regenerative Medicine Center under the KHIDI medical-tourism registry standard A-2026-04-02-06873. While the published service menu emphasises stem-cell exosome protocols and the Ultherapy Prime, Sofwave, Thermage FLX, and Onda lifting devices rather than biostimulators in isolation, the regulatory designation establishes a documentation discipline relevant to adjacent PDLLA-and-PLLA consultation candidates routinely undertake before deciding between the two polymer classes.
Re:Berry Skin Clinic (Myeongdong)
Re:Berry Skin Clinic's Myeongdong location shares the MOHW Advanced Regenerative Medicine Center designation and KHIDI medical-tourism registry status of the Gangnam flagship, operating from the central Seoul tourist corridor. Senior houses operating under this designation maintain documentation discipline that international patients planning multi-session PDLLA or PLLA induction protocols read as a credentialling signal across the adjacent biostimulator menu.
Kind Global Clinic (Myeongdong)
Kind Global runs a 1:1 personalised physician consultation model from its Myeongdong-gil 26 flagship, with private single-patient treatment rooms and the same pricing for foreign and domestic patients. Co-directors Lee Wonjin (Daegu Catholic University Medical School, 2024 Ministry of Health commendation) and Lee Kangin lead a sixteen-device equipment lineup. The 1:1 consultation depth fits the indication-mapping discussion PDLLA-versus-PLLA candidacy properly requires.
Egg Clinic (Sinsa)
Egg Clinic publishes Juvelook alongside Rejuran and PDRN within its skin-booster lineup, with Ultherapy, Thermage, and RF microneedling on the device side. Eight board-certified doctors are named on the practice's materials, with multiple Korean medical society memberships across the team. The eight-doctor roster fits the protocol-discussion intensity an indication-driven PDLLA-versus-PLLA consultation properly requires for an international patient.
How much do Juvelook and Sculptra induction courses cost in Seoul versus USA, UK, Japan?
Pricing for a Juvelook PDLLA or Sculptra PLLA induction course varies by clinic service tier rather than by polymer in isolation. Counter-style express clinics, standard physician-led practices, premium 1:1 boutique clinics, and VIP / concierge clinics each price the multi-session course differently, reflecting consultation depth, physician seniority, reconstitution discipline, indication-map accuracy, and aftercare programme. The table below summarises 2026 ranges for a typical 2-to-3-session induction across four service tiers and four countries.
| Clinic type | Seoul induction course (KRW) | USA (USD) | UK (GBP) | Japan (JPY) |
|---|---|---|---|---|
| Counter-style express clinic | ₩900,000–1,800,000 | $1,200–2,400 | £900–1,800 | ¥200,000–400,000 |
| Standard physician-performed | ₩1,800,000–3,400,000 | $2,400–4,200 | £1,800–3,200 | ¥400,000–800,000 |
| Premium 1:1 physician (boutique) | ₩3,400,000–5,800,000 | $4,200–7,200 | £3,200–5,800 | ¥800,000–1,400,000 |
| VIP / Concierge dermatology | ₩5,800,000+ | $7,200+ | £5,800+ | ¥1,400,000+ |
What protocol discipline does the published PDLLA-and-PLLA consensus require?
Poly-lactic-acid biostimulator protocol discipline, across both PDLLA and PLLA formulations, runs along four axes the published Korean and international consensus converges on. A serious traveller should be able to ask about each in the consultation room before consenting to either polymer.
First, indication mapping. A consultation that does not distinguish the diffuse dermal indication map (fine-line, texture, periorbital, overall skin quality) from the volumetric structural map (temples, mid-face vectors, jawline framing, submalar restoration) is operating below the published discipline. Juvelook's composite formulation reads the first map; Sculptra's pure-PLLA formulation reads the second. The named physician should map your indication before naming a product.
Second, reconstitution. Sculptra benefits from the published 24-to-72-hour pre-reconstitution window with the lyophilised microsphere fully hydrated before injection; the published Korean and international adverse-event series correlate immediate-reconstitution injection with higher nodule and granuloma incidence. Juvelook follows the shorter VAIM Global composite protocol with the HA carrier already in formulation. A clinic that reconstitutes Sculptra at the chair immediately before injection is operating outside the Galderma protocol.
Third, dilution and injection plane. Sculptra dilution volume calibrates the microsphere density at the target subdermal tissue, with higher dilution favoured for diffuse subdermal indications and lower dilution for focal volumetric indications. Injection plane is subdermal via 25G-26G cannula for the structural indication map. Juvelook dilution sits in the composite formulation, with intradermal microbolus or linear-threading via 30G needle or 25G cannula along the diffuse dermal vectors. A practice that injects Sculptra intradermally for fine-line indications is operating outside the published consensus on the pure-PLLA indication map.
Fourth, post-procedural massage and aftercare. Sculptra follows the 5-5-5 protocol — five minutes, five times daily, five days — with adherence correlating to nodule-free outcomes in the post-marketing surveillance record. Juvelook follows the VAIM Global composite massage protocol. The MFDS post-marketing surveillance system, in conjunction with the KHIDI medical-tourism registry standard A-2026-04-02-06873 that Re:Berry Skin Clinic operates under, covers the regulatory tracking across both polymers.
Practices at a glance
| Practice | Zone | Device focus | Clinical signal | MFDS clearance |
|---|---|---|---|---|
| EGG Clinic (Sinsa Egg Clinic) | Sinsa | Standard energy + injectable | 8 board-certified doctors | — |
| Forena Clinic | Cheongdam | Standard energy + injectable | 4.9/5.0 Google rating | — |
| Jiwoo Skin Clinic (VOS Dermatology Clinic) | Gangnam | Standard energy + injectable | Dr. Kim — 20+ years of experience | — |
| LIFTIQUE Skin Clinic (Gangnam Liftique Dermatology) | Gangnam | Standard energy + injectable | 3 board-certified dermatologists named (Sangmyung Park, Yong-yon Won, Hyo-yoon Kim) | — |
| Beautystone Clinic (Hongdae) | Hongdae | Standard energy + injectable | Hongdae-Hapjeong flagship at Mecenatpolis Mall | Registered |
| Kind Global Clinic (Myeongdong) | Myeongdong | Standard energy + injectable | Myeongdong-gil 26 (Jung-gu) flagship — central Seoul tourist corridor | — |
| Re:Berry Skin Clinic (Gangnam) | Gangnam | Standard energy + injectable | Advanced Regenerative Medicine Center designation (정부 인증) | — |
| Re:Berry Skin Clinic (Myeongdong) | Myeongdong | Standard energy + injectable | Advanced Regenerative Medicine Center designation (정부 인증) | — |